We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In this episode of ETF Spotlight, I talked with Brad Loncar, CEO of Loncar Investments. Brad created the Loncar Cancer Immunotherapy index and the China BioPharma index.
The 2018 Nobel Prize in medicine has been awarded to Dr. James P. Allison and Dr. Tasuku Honjo for their work on immunotherapy. In simple words, immunotherapy uses the body’s immune system to fight cancer.
There’s a lot of innovation going on in this space. We discussed the basics of immunotherapy, and why this therapy is called a gamechanger for cancer treatment.
Further, immunotherapy is not just one thing. There are many different types of immunotherapy like checkpoint inhibitors, vaccines and cell therapy. This excellent infographic from NYT shows how doctors are using immunotherapy to help the cells of the immune system recognize and attack cancer cells:
The Loncar Cancer Immunotherapy ETF (CNCR - Free Report) invests in companies at the forefront of immunotherapy research. It has 30 holdings, which are equally weighted. The expense ratio is 79 basis points.
Loncar Investments has also partnered with the Cancer Research Institute (CRI) and donates regular contributions to CRI.
We had talked about CNCR earlier this year. It was one of the top-performing ETFs then but has lost momentum in the past few months.
Looking at some of its holdings, we notice significant divergence in performance. Fate Therapeutics (FATE - Free Report) and Mirati Therapeutics are up more than 130% this year. On the other hand, Five Prime Therapeutics has plunged more than 40% and bluebird bio (BLUE - Free Report) is down more than 20%, year-to-date.
What do investors need to know about developments in this evolving space? Which companies are on Brad’s watchlist now? Find out on the podcast.
Healthcare was the top-performing sector in the third quarter but investors focused mainly on health insurers, pharmaceutical companies and medical device makers, and avoided riskier biotech stocks. Earlier this year, we saw a surge of M&A activity in the space, which has settled down of late. Can biotech stocks regain investor favor?
The Loncar China BioPharma ETF , which made its debut in August, focuses on the booming biopharma industry in China. Brad explained why investors need to look at this promising space.
To learn more about these ETFs, please visit loncarfunds.com.
Please also visit the Cancer Research Institute to learn about this cancer treatment and clinical trials.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Nobel Prize for Cancer Immunotherapy & Biotech ETFs to Buy
In this episode of ETF Spotlight, I talked with Brad Loncar, CEO of Loncar Investments. Brad created the Loncar Cancer Immunotherapy index and the China BioPharma index.
The 2018 Nobel Prize in medicine has been awarded to Dr. James P. Allison and Dr. Tasuku Honjo for their work on immunotherapy. In simple words, immunotherapy uses the body’s immune system to fight cancer.
There’s a lot of innovation going on in this space. We discussed the basics of immunotherapy, and why this therapy is called a gamechanger for cancer treatment.
Further, immunotherapy is not just one thing. There are many different types of immunotherapy like checkpoint inhibitors, vaccines and cell therapy. This excellent infographic from NYT shows how doctors are using immunotherapy to help the cells of the immune system recognize and attack cancer cells:
The Loncar Cancer Immunotherapy ETF (CNCR - Free Report) invests in companies at the forefront of immunotherapy research. It has 30 holdings, which are equally weighted. The expense ratio is 79 basis points.
Loncar Investments has also partnered with the Cancer Research Institute (CRI) and donates regular contributions to CRI.
We had talked about CNCR earlier this year. It was one of the top-performing ETFs then but has lost momentum in the past few months.
Looking at some of its holdings, we notice significant divergence in performance. Fate Therapeutics (FATE - Free Report) and Mirati Therapeutics are up more than 130% this year. On the other hand, Five Prime Therapeutics has plunged more than 40% and bluebird bio (BLUE - Free Report) is down more than 20%, year-to-date.
What do investors need to know about developments in this evolving space? Which companies are on Brad’s watchlist now? Find out on the podcast.
Healthcare was the top-performing sector in the third quarter but investors focused mainly on health insurers, pharmaceutical companies and medical device makers, and avoided riskier biotech stocks. Earlier this year, we saw a surge of M&A activity in the space, which has settled down of late. Can biotech stocks regain investor favor?
The Loncar China BioPharma ETF , which made its debut in August, focuses on the booming biopharma industry in China. Brad explained why investors need to look at this promising space.
To learn more about these ETFs, please visit loncarfunds.com.
Please also visit the Cancer Research Institute to learn about this cancer treatment and clinical trials.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>